• Revelation Biosciences Inc is joining Petra Acquisition Inc (NASDAQ: PAIC) to create a NASDAQ-listed company with an enterprise value of $128 million. 
• The merger is expected to close in Q4 2021, and the combined company will be listed on NASDAQ under the ticker symbol REVB.
• Revelation will pocket $73 million through the merger and use the money to advance REVTx-99, a nasal drop formulation designed to stimulate the innate immune system via TLR4-TRIF pathway agonism. 
• In a 48-subject phase 1 trial, Revelation linked REVTx-99 to increased intranasal levels of the cytokine IP-10. 
• Revelation identified IP-10 as the key cytokine of interest because it is upregulated in response to respiratory viral infection and linked to clinical efficacy in challenge studies. 
• With phase 1 proof-of-principle data in hand, Revelation is now gearing up for further development. 
• A 60-subject phase 2 influenza viral challenge study is slated to start in Q1 of 2022. 
• REVTx-99 is also in development to treat chronic nasal congestion, with a phase 1 trial set to start this year.
• The same platform has generated a second, earlier-stage candidate, REVTx-200. Revelation sees the follow-up prospect as a way to improve the immune response to intramuscular vaccines. 
• Price Action: PAIC stock is up 0.05% at $10.06 during the market session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga
• Anixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer
• See Why SmileDirectClub Stock Is Moving Higher On Monday

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.